新的脂肪因子asprosin会成为心血管疾病的代谢麻烦制造者吗?最先进的评论

IF 14 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Progress in lipid research Pub Date : 2023-07-01 DOI:10.1016/j.plipres.2023.101240

Zhengbin Zhang , Liwen Zhu , Ziqian Wang , Ning Hua , Shunying Hu , Yundai Chen

{"title":"新的脂肪因子asprosin会成为心血管疾病的代谢麻烦制造者吗?最先进的评论","authors":"Zhengbin Zhang , Liwen Zhu , Ziqian Wang , Ning Hua , Shunying Hu , Yundai Chen","doi":"10.1016/j.plipres.2023.101240","DOIUrl":null,"url":null,"abstract":"<div><p>Adipokines play a significant role in cardiometabolic diseases. Asprosin, a newly discovered adipokine<span>, was first identified as a glucose-raising protein hormone. Asprosin also stimulates appetite and regulates glucose and lipid metabolism. Its identified receptors so far include Olfr734 and Ptprd. Clinical studies have found that asprosin may be associated with cardiometabolic diseases. Asprosin may have diagnostic and therapeutic potential in obesity, diabetes, metabolic syndrome and atherosclerotic cardiovascular diseases. Herein, the structure, receptors, and functions of asprosin and its relationship with cardiometabolic diseases are summarized based on recent findings.</span></p></div>","PeriodicalId":20650,"journal":{"name":"Progress in lipid research","volume":"91 ","pages":"Article 101240"},"PeriodicalIF":14.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review\",\"authors\":\"Zhengbin Zhang , Liwen Zhu , Ziqian Wang , Ning Hua , Shunying Hu , Yundai Chen\",\"doi\":\"10.1016/j.plipres.2023.101240\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Adipokines play a significant role in cardiometabolic diseases. Asprosin, a newly discovered adipokine<span>, was first identified as a glucose-raising protein hormone. Asprosin also stimulates appetite and regulates glucose and lipid metabolism. Its identified receptors so far include Olfr734 and Ptprd. Clinical studies have found that asprosin may be associated with cardiometabolic diseases. Asprosin may have diagnostic and therapeutic potential in obesity, diabetes, metabolic syndrome and atherosclerotic cardiovascular diseases. Herein, the structure, receptors, and functions of asprosin and its relationship with cardiometabolic diseases are summarized based on recent findings.</span></p></div>\",\"PeriodicalId\":20650,\"journal\":{\"name\":\"Progress in lipid research\",\"volume\":\"91 \",\"pages\":\"Article 101240\"},\"PeriodicalIF\":14.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in lipid research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0163782723000309\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in lipid research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163782723000309","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

脂肪因子在心脏代谢疾病中起着重要作用。Asprosin是一种新发现的脂肪因子，最初被确定为一种血糖升高的蛋白质激素。芦笋素还能刺激食欲，调节葡萄糖和脂质代谢。目前发现的受体包括Olfr734和Ptprd。临床研究发现，asprosin可能与心脏代谢疾病有关。Asprosin可能在肥胖、糖尿病、代谢综合征和动脉粥样硬化性心血管疾病中具有诊断和治疗潜力。本文根据近年来的研究成果，综述了阿霉素的结构、受体、功能及其与心脏代谢疾病的关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review

Adipokines play a significant role in cardiometabolic diseases. Asprosin, a newly discovered adipokine, was first identified as a glucose-raising protein hormone. Asprosin also stimulates appetite and regulates glucose and lipid metabolism. Its identified receptors so far include Olfr734 and Ptprd. Clinical studies have found that asprosin may be associated with cardiometabolic diseases. Asprosin may have diagnostic and therapeutic potential in obesity, diabetes, metabolic syndrome and atherosclerotic cardiovascular diseases. Herein, the structure, receptors, and functions of asprosin and its relationship with cardiometabolic diseases are summarized based on recent findings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in lipid research 生物-生化与分子生物学

CiteScore

24.50

自引率

2.20%

发文量

审稿时长

14.6 weeks

期刊介绍： The significance of lipids as a fundamental category of biological compounds has been widely acknowledged. The utilization of our understanding in the fields of biochemistry, chemistry, and physiology of lipids has continued to grow in biotechnology, the fats and oils industry, and medicine. Moreover, new aspects such as lipid biophysics, particularly related to membranes and lipoproteins, as well as basic research and applications of liposomes, have emerged. To keep up with these advancements, there is a need for a journal that can evaluate recent progress in specific areas and provide a historical perspective on current research. Progress in Lipid Research serves this purpose.